ZOETIS INC. (ZTS) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry...
ZOETIS INC.'s revenue increased 2.3% year over year, from $9.26B to $9.47B.
Net income increased 7.5% over the same period, from $2.49B to $2.67B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 94% in total.
Total debt increased by 73.2% to $9.04B.
The debt-to-equity ratio stands at 2.71, indicating a high leverage profile.
Operating cash flow declined 1.7% to $2.90B.
ZOETIS INC. maintains a strong net profit margin of 28.2%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $2.39B+1.1% | $682.0M | $1.69B | $874.0M | $951.0M | $14.36B | $6.57B | $5.23B |
| Q4 FY2024 | $2.32B-3.0% | $581.0M | $1.61B | $732.0M | $905.0M | $14.20B | $5.22B | $4.77B |
| Q1 FY2025 | $2.22B-4.2% | $631.0M | $1.60B | $810.0M | $587.0M | $14.10B | $5.23B | $4.66B |
| Q2 FY2025 | $2.46B+10.8% | $718.0M | $1.81B | $902.0M | $486.0M | $14.48B | $5.23B | $4.98B |
| Q3 FY2025 | $2.40B-2.4% | $721.0M | $1.72B | $887.0M | $938.0M | $15.16B | $7.07B | $5.40B |
| Q4 FY2025 | $2.39B-0.5% | $603.0M | $1.68B | $761.0M | $893.0M | $15.50B | $9.04B | $3.33B |
| Q1 FY2026 | $2.26B-5.2% | $601.0M | $1.62B | $758.0M | $401.0M | $15.15B | $9.25B | $3.23B |
| Q2 FY2026 | $2.47B+9.1% | $691.0M | $1.79B | $1.07B | $655.0M | $15.08B | $9.26B | $3.15B |
Balance Sheet Summary (Q2 FY2026)
ZOETIS INC. (ZTS) Financial Statements & Revenue History
ZOETIS INC. (ZTS) is a US-listed stock operating in the Healthcare sector, specifically the Medical Devices industry trading at $80.00 with a market capitalization of $33. This page provides 42 historical financial statements for ZOETIS INC., including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, ZOETIS INC. reported revenue of $9.5 billion, representing 2.3% year-over-year growth. The net profit margin of 28.2% reflects strong profitability. The debt-to-equity ratio of 2.71 signals high leverage.
ZTS Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows ZOETIS INC.'s revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether ZTS is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track ZTS's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently ZOETIS INC. converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of ZTS's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use ZTS Financial Data
Investors use ZOETIS INC.'s financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare ZTS's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how ZTS's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View ZTS's financial health score, earnings, and pre-market pricing.
Financial data is sourced from ZOETIS INC.'s SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.ZTS trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.